Episode 26 - Kyle Felmet, Jennifer Lospinoso and the Art of Efficient Commercial Product Launch
Release Date: 10/30/2024
Episode 32 - Vinay Patel and the Invisible Factors Impacting Drug Prices at Pharmacies
The Future of Pharma
My guest in this episode is Vinay Patel. Vinay is a pharmacist executive with over 18 years in the field and founder of MakoRx. He has been involved with health management, community pharmacy operations, and creating pharmacy services. Vinay has worked in various pharmacy settings including national retail, local community, hospital pharmacy, academia, and group medical practices. His efforts now focus on scaling clinical pharmacy services within employer on-site clinics and bringing employers innovative Rx savings programs. Usually, I interview leaders from the pharmaceutical world, but...
info_outline
Episode 31 - Rene Marcotte and Leveraging Data in the Life Science Industry
The Future of Pharma
My guest in this episode is Rene Marcotte. Rene is Senior Vice President Life Sciences at RCM Technologies. Rene has nearly 40 years of experience as a data architect across multiple industries, including Life Sciences for the past 20 years. He has helped to lead and build over 40 data warehouses and analytic solutions, including for some of the largest and smallest pharmaceuticals. In this discussion, Rene and I talk about data aka the digital gold. Some of the topics we discussed are - The evolution of data over last few decades - Change in data hardware size and capabilities - How...
info_outline
Episode 30 - Dr. Mohit Jain, Biomarkers, and Precision Guided Medicine
The Future of Pharma
My guest in this episode is Dr. Mohit Jain, founder and CSO of Sapient. Dr. Jain is a physician-scientist with more than 20 years of expertise in physiology, computational biology, and mass spectrometry-based bioanalytics. He formed the Jain Laboratory at UCSD, where he led his team to develop next-generation mass spectrometry systems to probe the non-genetic landscape of disease across large-scale human studies. He founded Sapient in 2021 as a spinout of the Jain Laboratory to expand upon this mission, providing bespoke services multi-omics biomarker discovery. In this wide ranging yet...
info_outline
Episode 29 - Scott Chetham and the Future of Clinical Trials
The Future of Pharma
My guest in this episode is Scott Chetham. Scott is an experienced healthcare entrepreneur who is currently the CEO and co-founder of Faro Health. Scott leads the strategy for the Faro Health platform, which is designed to power clinical development by connecting data to decision making in a fundamentally new way. Previously, he was the Head of Clinical Research Operations and Data Management at Verily Life Sciences, formerly known as Google Life Sciences. His role involved leading the clinical strategy, clinical teams, process development and operations for all clinical...
info_outline
Episode 28 - Ron Gutman, New Technology in Healthcare and the Power of Smiling
The Future of Pharma
My guest today is Ron Gutman. Ron is an inventor, an investor, a serial technology and healthcare entrepreneur and a Stanford University adjunct Professor. Ron has built and invested in technology and healthcare companies that have served hundreds of millions of people and saved countless lives worldwide. He's an inventor holding a series of patents in healthcare technology and Artificial Intelligence and won the World Economic Forum Technology Pioneer award. Ron's articles have been published in respected media such as The Harvard Business Review, Forbes, Fortune Magazine, CNN,...
info_outline
Episode 27 - Nathan Clark and 10% Faster to the Market with Digitalization
The Future of Pharma
My guest in this episode is Nathan Clark. Nathan is the Co-Founder of Ganymede.bio, one of the fastest-growing software startups in biotech. Ganymede is the modern, data platform for life sciences companies, and its focused on integrating physical lab instruments with digital workflows. Prior to Ganymede, Nathan was the product manager at Benchling for Machine Learning and Insights Analytics. He also has a background in financial technology and trading, and notably launched affirm.com/savings. In this informative talk, Nathan and I talked about - His journey from being a bond...
info_outline
Episode 26 - Kyle Felmet, Jennifer Lospinoso and the Art of Efficient Commercial Product Launch
The Future of Pharma
I have two guests in today's episode, something I rarely do. My guests are Kyle Felmet and Jennifer Lospinoso. Kyle Felmet serves as the Vice President of Specialty Commercialization at Two Labs, an Envision Pharma Company, where he plays a pivotal role in ensuring that specialty drug manufacturers have the necessary distribution channel strategy infrastructure and pre-launch workstreams in place to facilitate a successful product launch with the appropriate wrap-around patient/prescriber services tailored to each unique product. His expertise spans across key therapeutic areas including...
info_outline
Episode 25 - Dr. Ben Coverdale and Using AI for Targeted Drug Discovery
The Future of Pharma
My guest today is Dr. Ben Coverdale. Ben is an experienced Global Account Director of Patsnap with a demonstrated history of working in the life sciences and innovation intelligence industries. Patsnap is Powered by advanced AI, where they help IP and R&D teams collaborate and accelerate the entire innovation lifecycle. He has a strong research professional background with a Doctor of Philosophy (PhD) focused in Biomedical Materials from The University of Manchester. He developed 3D scaffold fabrication methods for the regeneration of bone tissue, gaining insight in product...
info_outline
Episode 24 - Dr. Samuel Ewing and the New World of Digital Hospitals
The Future of Pharma
My guest in this episode is Dr. Samuel Ewing. He is the Global Head of Pharmaceutical Partnerships at Doccla. Before joining Doccla, Dr. Ewing led the development of a connected auto-injector system for Roche’s Alzheimer’s disease program at Capgemini Engineering. He also led the development of Biofourmis’s wearable vital sign monitoring platform. At Roche, he managed remote patient monitoring across various diseases, including Parkinson’s, Huntington’s, Alzheimer’s, Multiple Sclerosis, and others. As Chief Neuroscience Officer at NeuroPro, he developed a wearable brain monitoring...
info_outline
Episode 23 - Greg Kunst and Corneal Endothelial Therapy for Partial or Full Vision Loss
The Future of Pharma
My guest in this episode is Greg Kunst, CEO of Aurion Biotech. At Aurion, Greg and his colleagues are working on a regenerative treatment (corneal endothelial cell therapy) for millions of people who have partial or complete vision loss. Greg joined Aurion Biotech with deep and varied experience in ophthalmic medical devices, drug delivery systems, diagnostics, biotechnology, and pharmaceutical products. His expertise spans global corporate development, strategy, health policy, marketing, commercialization, business development, market access and medical affairs. Before Aurion Biotech, Greg...
info_outlineI have two guests in today's episode, something I rarely do. My guests are Kyle Felmet and Jennifer Lospinoso.
Kyle Felmet serves as the Vice President of Specialty Commercialization at Two Labs, an Envision Pharma Company, where he plays a pivotal role in ensuring that specialty drug manufacturers have the necessary distribution channel strategy infrastructure and pre-launch workstreams in place to facilitate a successful product launch with the appropriate wrap-around patient/prescriber services tailored to each unique product. His expertise spans across key therapeutic areas including oncology, rare diseases, and cell and gene therapies. Over the past decade, Kyle has been instrumental in supporting clients and vendors within these sectors, leading several successful product launches.
Jennifer Lospinoso is the Managing Director & Consulting Lead at Riparian. Jennifer brings 20 years of leadership experience in various areas of government and commercial program operations and compliance. Jennifer has extensive experience leading and delivering projects focused on U.S. government program regulatory compliance, gross-to-net forecasting and operational excellence.
In this wide-ranging talk, Kyle, Jennifer and I talk about
- Cell and gene therapy (CGT) pricing in the absence of insufficient historical data
- The challenges to set a price for CGT by the government and insurance companies
- Justification for high prices for CGT
- Outcome based reimbursements
- Expensive distribution logistics for CGT
- Why the product launch preparation starts 24-36 months before the actual launch date
- What start ups can do during the early phase to make product launch efficient and cost effective and
- Their favorite books and topics for their potential TedTalks.
This was an interesting discussion for me because we talked about where the science ends and the commercialization begins, something I haven't done.
I enjoyed my chat with Kyle and Jenn. Hope you do to.
Here's Kyle Felmet and Jennifer Lospinoso.